Latest News
Akebia Therapeutics, Inc.
- Why Is Akebia (NASDAQ:AKBA) Up 13.84% Premarket?
- Akebia Therapeutics (AKBA) Institutional Ownership 2026
- Akebia Therapeutics (Nasdaq:AKBA) - Stock Analysis
- Akebia Therapeutics, Inc. Announces Resignation of Nicholas Grund as Senior Vice President and Chief Commercial Officer, Effective November 6, 2026
- Nicholas Grund to Resign as Akebia's Chief Commercial Officer, Will Serve as Consultant
- The commercial chief at Akebia Therapeutics (AKBA) plans to resign for personal reasons.
- Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
- Akebia Therapeutics Announces Late-Breaking VOICE Trial
- Akebia Therapeutics (AKBA) Slips 3.28% to $0.88 as Shares Test Key Support - Retail Driven Moves
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp
Headlines from the last 30 days, linking to the original publishers. See all market news →